Blau Farmacêutica S.A

BLAU3 · SA · Healthcare / Drug Manufacturers - Specialty & Generic

9.78BRL-0.04 (-0.41%)

Price History

Full chart

Market Stats

Previous Close9.82

Open9.85

Day Range9.68 – 9.95

52-Week Range8.28 – 14.28

Volume226.90K

Market Cap2.50B

P/E (TTM)10.71

Forward P/E7.07

EPS1.01

Dividend Yield6.18%

Beta0.47

50-Day Avg9.47

200-Day Avg10.10

About

Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceuticals, oncologicals, hospital products, antivirals and antiretrovirals, biológicos, acid pump inhibitor, hemoderivatives, antithrombotic, and thrombolytics products. Blau Farmacêutica S.A. was incorporated in 1987 and is headquartered in Cotia, Brazil.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Marcelo Rodolfo Hahn
Employees0
HeadquartersRodovia Raposo Tavares, Cotia, SP, Brazil, 06705-030, Brazil
Websitehttps://www.blau.com

Leadership

Mr. Marcelo Rodolfo HahnFounder, Controller, CEO & Deputy Chairman
Mr. Douglas Leandro RodriguesAdministrative, Financial & Investor Relations Director
Mr. Roberto Carlos de Campos MoraisCOO, Chief M&A and Operations (USA and Europe) Officer & Director
Mr. Vanderlei SchiavoChief Technology, Digital Transformation & Innovation Officer
Mr. Roberto AltieriChief Legal Officer
Ms. Ana Luzia Marques IvanovChief People, Management & ESG Officer
Ms. Eliza Yukie SaitoChief Quality Officer
Ms. Eliana Sueco Tibana SamanoChief Medical Officer
Mr. Amaro Arialdo de Souza JuniorChief Business Unit Officer of Onco-Hematology and Specialties
Ms. Erica MalufChief Regulatory Affairs Officer

Financials

Income Statement

Currency: BRL	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	271.38M	299.07M	383.45M	430.93M	617.66M	782.16M	977.50M	1.18B	1.37B	1.41B	1.37B	1.75B	1.70B
Growth (%)	-	+10.20%	+28.21%	+12.38%	+43.33%	+26.63%	+24.97%	+20.90%	+15.62%	+2.96%	-2.44%	+27.81%	-2.96%
Cost of Revenue	180.43M	175.06M	223.20M	251.57M	337.22M	443.91M	547.43M	625.84M	700.47M	739.03M	882.38M	1.10B	1.05B
Gross Profit	90.96M	124.02M	160.25M	179.37M	280.43M	338.26M	430.06M	555.97M	665.93M	667.88M	490.25M	658.75M	652.52M
Gross Margin	33.52%	41.47%	41.79%	41.62%	45.40%	43.25%	44.00%	47.04%	48.74%	47.47%	35.72%	37.55%	38.33%
Operating Expense	52.77M	75.00M	105.31M	113.23M	117.35M	133.56M	128.78M	167.10M	209.06M	217.95M	278.71M	316.95M	322.77M
Operating Income	38.18M	49.02M	54.94M	66.13M	163.08M	204.69M	301.29M	388.86M	456.87M	449.93M	211.54M	341.80M	329.75M
Operating Margin	14.07%	16.39%	14.33%	15.35%	26.40%	26.17%	30.82%	32.90%	33.44%	31.98%	15.41%	19.48%	19.37%
EBITDA	46.60M	55.66M	53.38M	76.14M	170.42M	202.99M	311.41M	386.13M	530.17M	523.28M	405.23M	406.15M	394.08M
EBITDA Margin	17.17%	18.61%	13.92%	17.67%	27.59%	25.95%	31.86%	32.67%	38.80%	37.19%	29.52%	23.15%	23.15%
Net Income	15.20M	16.88M	23.06M	32.33M	103.13M	123.25M	200.24M	254.33M	325.22M	363.37M	249.81M	217.21M	294.95M
Net Income Margin	5.60%	5.64%	6.01%	7.50%	16.70%	15.76%	20.48%	21.52%	23.80%	25.83%	18.20%	12.38%	17.33%
R&D	-	-	-	13.59M	12.24M	15.28M	11.96M	28.54M	52.12M	38.91M	42.40M	30.25M	38.91M
R&D as % of Total Revenue	-	-	-	3.15%	1.98%	1.95%	1.22%	2.41%	3.81%	2.77%	3.09%	1.72%	2.29%
Interest Expense	9.11M	15.42M	21.58M	21.47M	13.01M	14.35M	16.21M	17.89M	30.14M	36.19M	37.58M	62.50M	75.03M
Interest Expense % of Total Revenue	3.36%	5.15%	5.63%	4.98%	2.11%	1.83%	1.66%	1.51%	2.21%	2.57%	2.74%	3.56%	4.41%

Balance Sheet

Currency: BRL	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	235.43M	262.11M	303.25M	315.72M	365.97M	594.15M	738.44M	1.27B	2.33B	2.50B	3.05B	3.41B	3.64B
Total Liabilities	168.27M	181.53M	219.55M	218.24M	227.63M	370.82M	472.69M	1.05B	693.16M	681.11M	1.06B	1.26B	1.38B
Total Equity	59.40M	71.48M	83.70M	97.49M	138.34M	223.33M	265.76M	221.34M	1.64B	1.82B	2.00B	2.16B	2.27B
Cash	14.19M	12.28M	10.04M	7.78M	9.16M	11.08M	6.42M	70.20M	51.86M	14.11M	31.50M	33.32M	45.60M
Total Debt	117.77M	127.71M	152.31M	141.91M	103.92M	225.13M	278.92M	690.96M	374.52M	311.71M	608.54M	558.95M	599.13M
Net Debt	103.58M	115.44M	142.27M	134.12M	94.75M	214.05M	272.50M	620.76M	322.65M	297.60M	577.04M	525.63M	553.53M

Cash Flow

Currency: BRL	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-2.74M	14.22M	17.06M	45.68M	126.63M	82.53M	221.29M	226.51M	153.98M	171.90M	188.06M	507.20M	222.24M
Investing Cash Flow	-16.56M	-18.27M	-42.43M	-16.85M	-40.34M	-153.25M	-146.63M	-216.01M	-870.32M	132.96M	-356.81M	-314.71M	-154.72M
Financing Cash Flow	12.97M	3.26M	21.48M	-27.35M	-88.06M	74.22M	-75.71M	57.26M	698.01M	-342.62M	186.09M	-190.67M	-51.70M
Capital Expenditure	13.35M	14.94M	20.52M	14.57M	36.07M	251.00K	13.46M	91.20M	177.77M	180.13M	114.97M	141.15M	262.04M
Free Cash Flow	-16.09M	-718.00K	-3.46M	31.10M	90.31M	82.28M	207.83M	135.31M	-23.80M	-8.23M	105.59M	366.06M	-39.80M
Dividends Paid	6.99M	4.25M	2.52M	12.71M	43.42M	33.38M	117.76M	326.92M	104.13M	135.52M	66.16M	56.11M	82.00M
FCF to OCF	587.15%	-5.05%	-20.28%	68.09%	71.32%	99.70%	93.92%	59.74%	-15.45%	-4.79%	56.15%	72.17%	-17.91%
Dividend Paid to FCF	-43.46%	-591.64%	-72.89%	40.87%	48.08%	40.57%	56.66%	241.60%	-437.61%	-1646.29%	62.66%	15.33%	-206.04%

Earnings

Report Date	Aug 9, 2021	Nov 7, 2021	Feb 20, 2022	May 8, 2022	Jul 31, 2022	Nov 2, 2022	Mar 1, 2023	May 4, 2023	Aug 8, 2023	Nov 8, 2023	Mar 19, 2024	May 6, 2024	Aug 5, 2024	Nov 5, 2024	Mar 19, 2025	May 5, 2025	Aug 4, 2025	Nov 4, 2025	Dec 31, 2025	May 7, 2026	Aug 11, 2026
EPS Estimate	0.42	0.35	0.46	0.45	0.41	0.42	0.65	0.47	0.39	0.33	0.25	0.15	0.19	0.26	0.34	0.26	0.29	0.31	0.26	0.24	0.33
EPS Actual	0.43	0.41	0.18	0.26	0.48	0.32	0.54	0.22	0.31	0.43	0.16	0.18	0.22	0.30	0.32	0.27	0.28	0.53	-	0.17	0.31
Surprise	2.38%	17.14%	-60.87%	-42.22%	17.07%	-23.81%	-16.92%	-53.19%	-20.51%	30.30%	-36.00%	20.00%	15.79%	15.38%	-5.88%	3.85%	-3.45%	70.97%	-	-29.17%	-6.06%
Timing	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	-	After-hours	After-hours	After-hours	-	After-hours	After-hours

Key Statistics & Ratios

Market Cap2.50B

Enterprise Value2.34B

Trailing P/E10.71

Forward P/E7.07

Price / Sales1.40

Price / Book1.02

EPS1.01

Book Value10.10

Revenue (TTM)1.79B

Gross Profit (TTM)738.36M

EBITDA356.22M

Profit Margin13.09%

Operating Margin17.13%

Return on Equity10.28%

Return on Assets5.15%

Shares Outstanding230.98M

Shares Float38.59M

Beta0.47

Dividend Yield6.18%

Dividend Rate0.66

Payout Ratio82.03%

Dividends

20262×

0.08Jun 25, 20260.08Mar 23, 2026

20254×

0.56Dec 18, 20250.11Dec 4, 20250.10Sep 23, 20250.25Mar 21, 2025

20244×

0.08Sep 26, 20240.14Jun 26, 20240.01Apr 29, 20240.13Mar 22, 2024

20233×

0.19Jun 27, 20230.05Apr 19, 20230.18Mar 24, 2023

20225×

0.18Dec 21, 20220.17Sep 26, 20220.16Jul 7, 20220.14Apr 7, 20220.21Mar 24, 2022

20213×

0.12Dec 3, 20210.11Sep 23, 20210.02Jul 5, 2021

Stock Splits

Jan 6, 202613:10